Oncology Institute Stock Alpha and Beta Analysis
| TOI Stock | USD 3.56 0.09 2.47% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Oncology Institute. It also helps investors analyze the systematic and unsystematic risks associated with investing in Oncology Institute over a specified time horizon. Remember, high Oncology Institute's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Oncology Institute's market risk premium analysis include:
Beta (0.77) | Alpha 0.24 | Risk 5.8 | Sharpe Ratio 0.0209 | Expected Return 0.12 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Oncology Institute Backtesting, Oncology Institute Valuation, Oncology Institute Correlation, Oncology Institute Hype Analysis, Oncology Institute Volatility, Oncology Institute History and analyze Oncology Institute Performance. Oncology Institute Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Oncology Institute market risk premium is the additional return an investor will receive from holding Oncology Institute long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncology Institute. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Oncology Institute's performance over market.| α | 0.24 | β | -0.77 |
Oncology Institute expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Oncology Institute's Buy-and-hold return. Our buy-and-hold chart shows how Oncology Institute performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Oncology Institute Market Price Analysis
Market price analysis indicators help investors to evaluate how Oncology Institute stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Oncology Institute shares will generate the highest return on investment. By understating and applying Oncology Institute stock market price indicators, traders can identify Oncology Institute position entry and exit signals to maximize returns.
Oncology Institute Return and Market Media
The median price of Oncology Institute for the period between Fri, Oct 3, 2025 and Thu, Jan 1, 2026 is 3.64 with a coefficient of variation of 12.94. The daily time series for the period is distributed with a sample standard deviation of 0.48, arithmetic mean of 3.7, and mean deviation of 0.39. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Why The Oncology Institute Inc. Equity Warrant stock remains a top recommendation - newser.com | 10/13/2025 |
2 | Real time alert setup for The Oncology Institute Inc. Equity Warrant performance - Quarterly Market Review Smart Allocation Stock Tips - newser.com | 11/03/2025 |
3 | Ascertain and The Oncology Institute Co-Develop Touchless AI Automation for Oncology Administration | 11/13/2025 |
4 | The Oncology Institute Inc Q3 2025 Earnings Call Highlights Revenue Surge and AI ... | 11/14/2025 |
5 | Acquisition by Robert Carter of 195 shares of Oncology Institute subject to Rule 16b-3 | 11/17/2025 |
6 | Disposition of 590892 shares by M33 Growth I L.p. of Oncology Institute subject to Rule 16b-3 | 11/18/2025 |
7 | Acquisition by Hively Brad of 41667 shares of Oncology Institute subject to Rule 16b-3 | 11/20/2025 |
8 | A Mysterious Stock Has Rallied Over 950 percent This Year. Heres 1 Key Reason Why Investors Are Turning Bullish | 11/21/2025 |
9 | Acquisition by Kaushal Mohit of 40123 shares of Oncology Institute subject to Rule 16b-3 | 11/24/2025 |
10 | Rutgers Health Administrator Shares Her Own Breast Cancer Story - Rutgers University | 12/03/2025 |
11 | Disposition of 13333 shares by Hively Brad of Oncology Institute at 3.7719 subject to Rule 16b-3 | 12/15/2025 |
12 | Oncology Institute Director Makes Significant Stock Sale - TipRanks | 12/16/2025 |
13 | Will The Oncology Institute Inc. Equity Warrant stock reach Wall Street targets - Long Setup Weekly Watchlist for Hot Stocks - | 12/19/2025 |
About Oncology Institute Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Oncology or other stocks. Alpha measures the amount that position in Oncology Institute has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0118 | 0.0105 | Price To Sales Ratio | 0.0589 | 0.056 |
Oncology Institute Upcoming Company Events
As portrayed in its financial statements, the presentation of Oncology Institute's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oncology Institute's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Oncology Institute's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Oncology Institute. Please utilize our Beneish M Score to check the likelihood of Oncology Institute's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Oncology Institute
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Oncology Institute Backtesting, Oncology Institute Valuation, Oncology Institute Correlation, Oncology Institute Hype Analysis, Oncology Institute Volatility, Oncology Institute History and analyze Oncology Institute Performance. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Oncology Institute technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.